Clinical trials: Auto Stem Cell Transplant
Acute Lymphoblastic Leukemia ALL
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the…
- Trial name
- NCT06608342
- Testing
- Autologous hematopoietic stem cell transplantation combined with CD19-CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory…
- Trial name
- NCT03707847
- Testing
- Crizotinib, Etoposide Capsule, Auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Large B-cell Lymphoma, CAR T Cell Therapy
Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT
The goal of this clinical trial is to learn if sequential CD19/CD22 CAR-T cell therapy following autologous stem cell transplantation (ASCT) works to treat relapsed or refractory large B-cell lymphoma (LBCL) in adults.
- Conditions
- Large B-cell Lymphoma, CAR T Cell Therapy, Auto Stem Cell Transplant
- Trial name
- NCT07236151
- Testing
- Apheresis and Bridging Therapy, Conditioning and Stem Cell Transplantation, CAR-T Cell Administration
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
The goal of this clinical trial is to learn if high-dose Melphalan HCl for Injection works to treat multiple myeloma. It will also learn about the safety of high dose Melphalan HCl for Injection.
- Trial name
- NCT06425276
- Testing
- Melphalan Hydrochloride for Injection
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CASI Pharmaceuticals (China) Co., Ltd.
Delayed Platelet Engraftment, Neuroblastoma
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06818916
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Children's Hospital
Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched donors.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning
- Trial name
- NCT02671708
- Testing
- Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma
- Trial name
- NCT03385096
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lymphoma, Multiple Myeloma
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell…
- Trial name
- NCT03383055
- Testing
- CMV-MVA Triplex Vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Intestinal Mucositis, Inflammation
Semaglutide in Auto-HSCT
The primary objective of this clinical trial is to ievaluate the effect of semaglutide (GLP-1 receptor agonist) in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by…
- Conditions
- Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity
- Trial name
- PROTECT (NCT06449625)
- Testing
- Semaglutide Pen Injector [Ozempic]
- Volunteers
- 40 people
- Sponsor
- Klaus Gottlob Müller
Multiple Myeloma
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune…
- Trial name
- PCV13 (NCT01852591)
- Testing
- PCV 13
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
- Trial name
- NCT00702247
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Diffuse Large B Cell Non-Hodgkin Lymphoma
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
This is a single institution phase I/II study using an ADAM17 inhibitor (INCB7839) with rituximab as consolidation therapy after an autologous hematopoietic cell transplant (HCT) for patients with diffuse large B cell lymphoma…
- Trial name
- NCT02141451
- Testing
- Rituximab, INCB7839
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
T-cell Non-Hodgkin Lymphoma
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
The current standard of care for the frontline treatment of peripheral T-cell lymphomas (PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT).
- Trial name
- NCT01746173
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Large B-Cell Lymphoma
R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed patients with DLBCL with intermediate…
- Trial name
- NCT02842931
- Testing
- R-DA-EPOCH-21, R-DA-EPOCH-21 + auto-SCT, R-mNHL-BFM-90
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- National Research Center for Hematology, Russia
Multiple Myeloma
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
In this protocol, the investigators hypothesize that the combination of intravenous busulfan and melphalan with carfilzomib will be an effective preparative regimen with acceptable toxicity for participants with multiple myeloma…
- Trial name
- BuMelCarAuto (NCT03795597)
- Testing
- Carfilzomib, Busulfan IV, Melphalan IV
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Loyola University
Multiple Myeloma
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
The goal of this clinical research study is to learn if curcumin can reduce the symptoms reported by patients with multiple myeloma (MM) who receive treatment with lenalidomide.
- Trial name
- NCT01269203
- Testing
- Curcumin
- Sponsor
- M.D. Anderson Cancer Center
Peripheral T Cell Lymphoma
Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the autologous hematopoietic stem cell transplantation group…
- Trial name
- T-START-PR (NCT07253129)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Allogenic stem cell transplant (ASCT)
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Effects of Chemotherapy
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation
- Trial name
- NCT02306837
- Testing
- Bu-CY-E
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital